Statin use is linked to increased risk of developing diabetes, warn researchers

May 23, 2013

Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.

Statins are among the most widely prescribed medications for the prevention of . Although tolerated well, an association with new-onset diabetes has recently been suggested. One trial suggested a 27% increased risk of diabetes with rosuvastatin whereas another suggested patients taking pravastatin benefitted from a 30% lower risk.

As there is limited data on this subject, researchers from Canada carried out a population-based study on 1.5 million residents in Ontario, Canada to examine the association between individual statin use and new-onset diabetes.

All patients were aged 66 and over and started statin therapy between 1997 and 2010. The was 73 years. Follow up ended either at the end of 2010 or a maximum of five years following the initiation of statins, whichever came first. The primary outcome was incident diabetes.

Data were taken from the Ontario Drug Benefit database, the Canadian Institute for Discharge Abstract Database and the Ontario Diabetes Database. Statins included in the study were: fluvastatin, , pravastatin, simvastatin, atorvastatin and rosuvastatin.

All studies used pravastatin-treated patients as the comparison group as this has been shown to have favourable effects on newly diagnosed diabetes in animal models and clinical trials.

471,250 patients were identified with no history of diabetes and who were newly treated with a statin. 54% were women. Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin.

The overall risk of developing diabetes was low but this risk was increased among some patients taking statins. Between 162 and 407 patients would have to be treated with the various statins for one extra patient to develop diabetes. Patients treated with atorvastatin were found to have a 22% increased risk of new-onset diabetes, rosuvastatin an 18% increased risk and simvastatin a 10% increased risk, relative to pravastatin. In contrast, patients treated with fluvastatin were at a 5% decreased risk and lovastatin a 1% decreased risk.

The event rate was highest for atorvastatin (30 outcomes per 1000 person-years) and (34 per 1000 person-years). Simvastatin accounted for 26 outcomes per 1000 person-years with both fluvastatin and lovastatin at 21 outcomes per 1000 person-years.

The researchers found consistent results in analyses examining the use of statins for primary prevention (when those without established disease are treated) and secondary prevention (when those with established disease are treated). Their findings also suggest that older patients are at an increased risk regardless of dose for and or whether therapy is used for primary or secondary prevention.

The researchers say several factors may explain the increased risk of new-onset diabetes among patients receiving certain statins including impaired insulin secretion and inhibited insulin release.

In conclusion, the researchers say clinicians should consider risk when contemplating statin therapy. They add that "preferential use of pravastatin, and potentially fluvastatin […] may be warranted" and that may even be beneficial to patients at high risk of diabetes.

In an accompanying editorial, doctors from the University of Turku in Finland say that "the overall benefit of statins still clearly outweighs the potential risk of incident ". They conclude that as statins have been shown to reduce cardiovascular events in patients, they "play an important role in treatment".

Explore further: Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes

More information: Risk of incident diabetes among patients treated with statins: population based study, BMJ, 2013.
Editorial: Statins and the risk of developing diabetes, BMJ, 2013.

Related Stories

Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes

April 10, 2013
(Medical Xpress)—A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.

High potency statins pose significantly higher risk of kidney injury than low potency, say experts

March 19, 2013
Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today in BMJ suggests.

Risk of new-onset diabetes varies with different statins

April 11, 2013
(HealthDay)—Different types and doses of statins seem to correlate with distinct risks of developing new-onset diabetes mellitus (DM), according to a meta-analysis published in the April 15 issue of The American Journal ...

Cholesterol-lowering drug may reduce exercise benefits for obese adults, study finds

May 15, 2013
Statins, the most widely prescribed drugs worldwide, are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders ...

Cardiovascular benefits of taking statins outweigh diabetes risk

August 9, 2012
The benefits of taking statins to reduce the risk of cardiovascular disease outweigh the increased risk of developing diabetes experienced by some patients who take these cholesterol-lowering drugs, according to an Article ...

Statin use in postmenopausal women associated with increased diabetes risk

January 9, 2012
The use of statins in postmenopausal women is associated with increased diabetes risk, according to a study published Online First by the Archives of Internal Medicine.

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.